XW001 / Sciwind Biosci - LARVOL DELTA

Discovery and Optimization of Novel Apo-IDO1 Inhibitors by a Pharmacophore-Based Structural Simplification Strategy. (PubMed, J Med Chem) - "Here, we present the identification of the thienopyrimidine derivative XW-001 through structure-based virtual screening, followed by an iterative optimization process that led to the development of XW-032. XW-032 exhibited remarkable in vitro inhibitory activity against apo-IDO1 (IC50 = 21 ± 5 nM) through a pharmacophore-guided structural simplification approach. Notably, XW-032 (TGI = 63%) exhibited potent in vivo antitumor efficacy in the CT26 syngeneic mouse model, highlighting the benefits of apo-IDO1 inhibitors for tumor immunotherapy."

Journal • Oncology

Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Sciwind Biosciences APAC CO Pty. Ltd. | N=120 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.

New P1/2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Phase Ia Study of Single Dose and Multiple Doses of XW001 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=81 | Completed | Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.

New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections